Yixintang Pharmaceutical (SZ:002727) Xin Lang Cai Jing·2026-01-12 01:40Core Viewpoint - YXTT's stock performance shows a slight increase of 0.61% on January 9, with a trading volume of 145 million yuan, indicating a stable market interest in the company [1] Financing Summary - On January 9, YXTT had a financing buy-in amount of 16.44 million yuan and a financing repayment of 14.24 million yuan, resulting in a net financing buy of 2.20 million yuan [1] - As of January 9, the total financing and margin trading balance for YXTT is 266 million yuan, with the financing balance accounting for 3.40% of the circulating market value, which is above the 80th percentile of the past year [1] - In terms of margin trading, YXTT repaid 2,400 shares on January 9, with no shares sold, and the margin balance is 1.15 million yuan, also exceeding the 80th percentile of the past year [1] Business Performance - As of September 30, YXTT reported a total revenue of 13 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 4.33%, while the net profit attributable to shareholders was 269 million yuan, down 8.17% year-on-year [2] - Since its A-share listing, YXTT has distributed a total of 2.02 billion yuan in dividends, with 764 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, YXTT has 37,500 shareholders, an increase of 10.53% from the previous period, with an average of 10,596 circulating shares per shareholder, down 9.53% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 22.31 million shares, an increase of 3.74 million shares from the previous period [3] - New institutional shareholders include several funds, such as Xingquan Trend Investment Mixed Fund and Rongtong Health Industry Flexible Allocation Mixed Fund, indicating growing institutional interest in YXTT [3]